Papers

4

Total Citations

488

H-Index

4

About

Vesa Kataja is a leading Finnish oncologist whose work has shaped international standards for the diagnosis and treatment of genitourinary cancers. His primary research areas encompass urological oncology, clinical practice guidelines, and the application of advanced radiotherapy techniques. Kataja’s most significant contributions include his pivotal role in authoring the ESMO Clinical Practice Guidelines for renal cell carcinoma (275 citations) and prostate cancer (164 citations), which serve as essential, evidence-based frameworks for clinicians worldwide. Beyond guideline development, he has been at the forefront of adopting hypofractionated stereotactic body radiotherapy (SBRT) for localized prostate cancer. His pioneering work, including the first Nordic clinical experience and subsequent five-year efficacy results (with 26 and 23 citations respectively), provided crucial real-world data demonstrating the safety and long-term effectiveness of this high-precision, non-invasive treatment. By bridging rigorous guideline creation with innovative clinical implementation, Kataja has directly improved patient outcomes and advanced the standard of care in radiation oncology.

Research Focus

Key Achievements

4
H-Index
4
Papers
488
Total Citations
122
Avg Citations/Paper
🏆 Most Cited Paper
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
275 citations · 2012
📈 Most Prolific Year: 2012 (1 Papers)
🤝 Key Collaborators: 20
🏛 Institutions: Kuopio University Hospital, Central Finland Health Care District, University of Eastern Finland

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago